Sunday, November 1, 2026

Back to today

From X

@StableBread

Fajasy on X

35% of TOYO Co., Ltd’s $TOYO H1 2026 revenue came from one customer it doesn’t name, and 22% came from companies under its own controlling shareholder. $TOYO manufactures solar cells, the processed silicon wafers that turn sunlight into electricity, and assembles some of them into panels (modules). Its cells use TOPCon (tunnel oxide passivated contact), a common high-efficiency silicon cell design. $TOYO runs three factories: 1) Ethiopia (4 GW of cells): Started production in April 2025, six months after $TOYO announced the plant, added a second 2 GW line in August, and reached its 4 GW nameplate in October 2025. 2) Vietnam (2 GW of cells): Running since H2 2023, but its cells now go to non-U.S. markets like India and Taiwan, since the U.S. Commerce Department set anti-dumping and countervailing duties (taxes on imports sold below cost or subsidized) on Vietnamese cells in April 2025. 3) Texas (2 GW of modules): A leased 567,140-square-foot plant near Houston that started its first 1 GW line in October 2025 and had completed its second by early October 2026. It assembles panels from $TOYO’s Ethiopian cells. VSUN (Vietnam Sunergy JSC) is the Vietnamese panel maker $TOYO was carved out of, and both companies sit under the same majority shareholder, Abalance, a Japanese solar group. VSUN is still $TOYO’s lender, owed $51.4M including interest, and a past wafer supplier through its Chinese subsidiary. $TOYO’s $261.0M of H1 2026 revenue came from four lines: → Third-party cells (56.5%): $147.6M of cells sold to outside module makers. → Related-party sales (22.0%): $57.5M of cells and modules sold to VSUN and its affiliates. → OEM services (14.2%): $37.2M of fees for cells made under one customer’s name, which $TOYO books net, counting only its fee as revenue. → Third-party modules (7.2%): $18.7M of Texas-made panels. Upstream, 70% of the polysilicon (the refined silicon that wafers are cut from) in $TOYO’s Ethiopian cells comes from a U.S. producer and the rest from OCI’s plant in Malaysia, Rhone Resch, $TOYO’s Chief Strategy Officer, said on the Q2 call. Resch also said its 2026 wafers come from non-China production, “including a designated facility in Indonesia.” $TOYO markets its supply chain as “non-FEOC,” free of any foreign entity of concern. U.S. buyers care, since the One Big Beautiful Bill Act (OBBBA) denies the main clean-power tax credit to projects with too much equipment from Prohibited Foreign Entities, a label aimed at Chinese suppliers.
@SouthernValue95 1 click

SouthernValue on X

Ramp data shows VC-backed companies are spending 10x more per employee/month on AI vs. PE-owned and other companies. A bearish interpretation could be: token spend is being driven by VC-backed companies, making demand vulnerable to swings in capital cycle. Valid! However, on a longer timeframe, I think this is quite interesting as a leading indicator for the direction of software companies (VC-backed companies are mostly software or service-as-software companies). New companies are being built with a larger ratio of tokens vs. humans. Look at Anthropic itself, which pays 1/6 as much on intelligence as its customers (since it sells tokens marked up at 85% GM): Anthropic is spending ~9x more on compute than human salaries despite having access to tokens at cost. Cash payroll is annualizing ~$2B for a company with ~$60B of run-rate revenue in 1H26. Anthropic employs just 5k people. Wild efficiency in human capital. I suspect that the great software companies of the next decade, both new and incumbent, will insert AI into every aspect of their products so that using them feels like magic, and work happens seamlessly. Building a presentation in Claude feels like magic: I tell it what I want to put on a slide, and it appears like magic. As a user of Ramp, their products feel the same way: I make a purchase, take a picture of a receipt, and the expense is logged into my accounting system appropriately without the need for a human to type into a blank box. I think we will see most software become AI-native or be replaced by software that is. This is a significant opportunity for incumbents and startups alike. And I think this is a huge source of future token spend that will go to $AMZN and $GOOG where most software companies are built (on AWS and GCP) and where AMZN and GOOG are building the platforms for software companies to build AI capabilities into their products with choice around compute and model, embedded safety and governance, and unlimited scale. Amazon CEO @ajassy said on a podcast this week that AI spend is currently a "barbell-shape" with insatiable compute appetite of the AI labs on one side, and corporates using AI for cost savings on the other. In the middle is tokens embedded into "core workloads" which he says is growing but small today, but he thinks in 5 years might be the biggest category of token spend.

Altria: Dutiful

Altria raised 2026 adjusted EPS guidance to $5.66 to $5.74 and authorized more buybacks, while on! loses share as cigarette margins hold.

When the liquidity does not add up

Arbor Realty Trust’s dividend suspension is presented as creating $60 million of liquidity, raising questions about its ability to meet…

Verra veerer

Verra Mobility’s Avis termination threatens 2027 earnings, while Government Solutions profit rose 25% and implied fourth-quarter guidance…

FTAI 3Q26: Aero margins in focus

FTAI’s Aerospace Products margin rebounded to 31% as CFM56 module output rose, while Power deposits and contracted deliveries fund its 2027…

Microsoft's AI Boom Has A Cost

Microsoft’s Azure grew 48% as AI monetization accelerated, but doubled CapEx, largely for CPUs and GPUs, reduced quarterly free cash flow…

T · short

At&t INC

AT&T’s stalled deleveraging and share repurchase case has prompted a bearish turn on the telecom stock.

CVX Earnings Review

Chevron’s Q3 revenue rose 35% to $65.2 billion and EBITDA 75% to $20.2 billion, while production trailed guidance and refining margins…

SNY Earnings Review

Sanofi raised FY26 guidance after Q3 sales grew 14.3% at constant currency, led by 34.8% Dupixent growth; vaccines declined 6.6%.

Publications we follow

Every publication on this site, hand-picked.

129 publications

Newsletters 109

X accounts we follow

Every account on this site, hand-picked.

91 accounts

Investor letters we follow

190 firms

Sectors

Ordered by how often our editor reaches for them.